- Conditions
- IgG Deficiency, Infections
- Interventions
- IV Gamunex 10%
- Drug
- Lead sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Crohn Disease
- Interventions
- Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
- Drug · Procedure · Biological
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 13 Years to 28 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Exposure During Pregnancy
- Interventions
- A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
- Conditions
- Multiple Myeloma, Secondary Immunodeficiency
- Interventions
- IGI, 10%
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
- Conditions
- Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
- Interventions
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Primary Immunodeficiency
- Interventions
- IGIV-C 10%, IGSC 20%
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 2 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 13
- States / cities
- Cypress, California • Irvine, California • Los Angeles, California + 10 more
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
- Interventions
- Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG)
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 35 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Recombinant human hyaluronidase + immune globulin intravenous
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 3
- States / cities
- Centennial, Colorado • North Palm Beach, Florida • Dallas, Texas